Patents by Inventor Roi Mashiach

Roi Mashiach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antimicrobial compositions comprising minocycline and degradation products of oxidized cellulose
    Patent number: 11690937
    Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: July 4, 2023
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Antimicrobial compositions comprising minocycline and oxidized cellulose
    Patent number: 11654217
    Abstract: Disclosed are compositions comprised of Oxidized Cellulose (OC), such as oxidized regenerated cellulose (ORC), and an antibiotic comprised of minocycline, methods of preparation thereof and uses thereof.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: May 23, 2023
    Assignees: OMRIX BIOPHARMACEUTICALS LTD., ETHICON, INC.
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • ANTIMICROBIAL COMPOSITIONS COMPRISING MINOCYCLINE AND DEGRADATION PRODUCTS OF OXIDIZED CELLULOSE
    Publication number: 20210316048
    Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.
    Type: Application
    Filed: June 11, 2021
    Publication date: October 14, 2021
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • ANTIMICROBIAL COMPOSITIONS COMPRISING MINOCYCLINE AND OXIDIZED CELLULOSE
    Publication number: 20210228783
    Abstract: Disclosed are compositions comprised of Oxidized Cellulose (OC), such as oxidized regenerated cellulose (ORC), and an antibiotic comprised of minocycline, methods of preparation thereof and uses thereof.
    Type: Application
    Filed: April 12, 2021
    Publication date: July 29, 2021
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Antimicrobial compositions comprising minocycline and degradation products of oxidized cellulose
    Patent number: 11045588
    Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 29, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • Antimicrobial compositions comprising minocycline and oxidized cellulose
    Patent number: 11000635
    Abstract: Disclosed are compositions comprised of Oxidized Cellulose (OC), such as oxidized regenerated cellulose (ORC), and an antibiotic comprised of minocycline, methods of preparation thereof and uses thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 11, 2021
    Assignees: Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • RNA polymerase I inhibitors and uses thereof
    Patent number: 10993948
    Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: May 4, 2021
    Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Anat Achiron, Roi Mashiach, Michael Gurevich
  • ANTIMICROBIAL COMPOSITIONS COMPRISING MINOCYCLINE AND OXIDIZED CELLULOSE
    Publication number: 20190184068
    Abstract: Disclosed are compositions comprised of Oxidized Cellulose (OC), such as oxidized regenerated cellulose (ORC), and an antibiotic comprised of minocycline, methods of preparation thereof and uses thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 20, 2019
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • ANTIMICROBIAL COMPOSITIONS COMPRISING MINOCYCLINE AND DEGRADATION PRODUCTS OF OXIDIZED CELLULOSE
    Publication number: 20190184069
    Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 20, 2019
    Inventors: Eve Montia, Dwayne Looney, Theresa Scheuble, Ronen Eavri, Roi Mashiach
  • RNA POLYMERASE I INHIBITORS AND USES THEREOF
    Publication number: 20180264002
    Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.
    Type: Application
    Filed: June 4, 2018
    Publication date: September 20, 2018
    Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Anat Achiron, Roi Mashiach, Michael Gurevich
  • RNA polymerase I inhibitors and uses thereof
    Patent number: 10022382
    Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: July 17, 2018
    Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Anat Achiron, Roi Mashiach, Michael Gurevich
  • RNA POLYMERASE I INHIBITORS AND USES THEREOF
    Publication number: 20170290842
    Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.
    Type: Application
    Filed: June 19, 2017
    Publication date: October 12, 2017
    Applicant: Tel HaShomer Medical Research Infrastructure and Services, Ltd.
    Inventors: Anat ACHIRON, Roi MASHIACH, Michael GUREVICH
  • RNA polymerase I inhibitors and uses thereof
    Patent number: 9688697
    Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: June 27, 2017
    Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Anat Achiron, Roi Mashiach, Michael Gurevich
  • RNA POLYMERASE I INHIBITORS AND USES THEREOF
    Publication number: 20150284410
    Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.
    Type: Application
    Filed: June 18, 2015
    Publication date: October 8, 2015
    Inventors: Anat ACHIRON, Roi Mashiach, Michael Gurevich